Venatorx Pharmaceuticals Expands Anti-Infective Portfolio with HBV Candidate 

VNRX-9945 Selected as 3rd Generation Hepatitis B Virus Orally Bioavailable CpAM; Clinical Trial Application and Phase 1 Planned for Second Quarter 2021  

See more here